Arformoterol - Revision history

Prab: CSV import

2025-03-23T11:37:51Z

CSV import

← Older revision		Revision as of 11:37, 23 March 2025
Line 1:		Line 1:
	~~== Apararenone ==~~		{{Short description\|A long-acting beta-adrenoceptor agonist used in the treatment of chronic obstructive pulmonary disease}}

	~~'''Apararenone''' is a pharmaceutical compound that acts as a~~ [[~~mineralocorticoid receptor antagonist]]. It is primarily used in the treatment of conditions such as [[hypertension]] and [[heart failure]]~~. ~~Apararenone works by blocking the action~~ of ~~[[aldosterone~~]]~~, a hormone that increases the reabsorption of sodium and water in the kidneys, leading to increased blood pressure.~~		[[File:Arformoterol.svg\|Chemical structure of Arformoterol\|thumb\|right]]

	~~=== Mechanism of Action ===~~		'''Arformoterol''' is a [[long-acting beta-adrenoceptor agonist]] (LABA) used in the management of [[chronic obstructive pulmonary disease]] (COPD). It is the (R,R)-enantiomer of [[formoterol]], which is responsible for the drug's bronchodilatory effects. Arformoterol is marketed under the brand name Brovana and is administered via inhalation.
	~~Apararenone functions by competitively inhibiting~~ the ~~binding~~ of ~~aldosterone to the mineralocorticoid receptor~~. ~~This inhibition prevents~~ the ~~activation~~ of ~~the receptor~~, ~~thereby reducing sodium reabsorption and promoting~~ the ~~excretion of sodium and water~~. ~~This action helps to lower blood pressure~~ and ~~reduce the workload on the heart~~.

	==~~= Clinical Uses =~~==		==Pharmacology==
	~~Apararenone is used~~ in the ~~management of:~~		Arformoterol works by stimulating [[beta-2 adrenergic receptors]] in the [[bronchial smooth muscle]], leading to muscle relaxation and bronchodilation. This action helps to alleviate symptoms of COPD such as shortness of breath and wheezing.
	* [[~~Hypertension~~]]~~: By reducing blood volume and vascular resistance~~, ~~apararenone helps~~ to ~~lower blood pressure~~.
	* [[Heart failure]]: It helps ~~in reducing the~~ symptoms of ~~heart failure by decreasing fluid overload~~ and ~~improving cardiac function~~.

	~~=== Pharmacokinetics ===~~		[[File:Arformoterol_ball-and-stick_model.png\|Ball-and-stick model of Arformoterol\|thumb\|left]]
	~~Apararenone is administered orally~~ and ~~is absorbed in the gastrointestinal tract~~. ~~It undergoes hepatic metabolism~~ and ~~is excreted primarily through the kidneys. The pharmacokinetic profile~~ of ~~apararenone allows for once-daily dosing, which can improve patient compliance.~~

	=== ~~Side Effects~~ ===		===Mechanism of Action===
	~~Common side effects of apararenone include:~~		The drug binds to beta-2 adrenergic receptors, which are G protein-coupled receptors located on the surface of bronchial smooth muscle cells. Upon activation, these receptors initiate a cascade of intracellular events that result in the relaxation of smooth muscle fibers, thereby dilating the airways and improving airflow.
	* [[Hyperkalemia]]: Due to ~~its potassium~~-~~sparing effects~~, ~~there is~~ a ~~risk~~ of ~~elevated potassium levels~~ in the ~~blood.~~
	* [[Hypotension]]: Excessive lowering of ~~blood pressure can occur~~, ~~especially in patients with pre-existing low blood pressure.~~
	* [[Dizziness]] and ~~[[fatigue]]: These are common due to the blood pressure-lowering effects~~.

	=== ~~Contraindications~~ ===		===Pharmacokinetics===
	~~Apararenone should not be used in patients with:~~		Arformoterol is administered via inhalation, allowing for direct delivery to the lungs. It has a rapid onset of action, typically within 20 minutes, and its effects can last up to 12 hours, making it suitable for twice-daily dosing. The drug is metabolized primarily in the liver and excreted in the urine.
	* Severe [[renal impairment]]
	* [[Hyperkalemia]]
	* Known hypersensitivity to the drug

	==~~= Drug Interactions =~~==		==Clinical Use==
	~~Apararenone can interact~~ with ~~other medications that affect potassium levels~~, ~~such as [[ACE inhibitors]]~~ and ~~[[potassium supplements]]~~. ~~Caution~~ is ~~advised when used concurrently with these agents~~.		Arformoterol is indicated for the long-term maintenance treatment of bronchoconstriction in patients with COPD, including chronic bronchitis and emphysema. It is not intended for the relief of acute bronchospasm or for the treatment of asthma.

	== ~~Related Pages~~ ==		==Side Effects==
	* [[Mineralocorticoid receptor antagonist]]		Common side effects of arformoterol include tremor, nervousness, and headache. As with other beta-agonists, it may cause cardiovascular effects such as increased heart rate and blood pressure. Patients should be monitored for signs of worsening asthma or paradoxical bronchospasm.
	* [[Aldosterone]]
	* [[Hypertension]]
	* [[Heart failure]]

	== ~~Gallery~~ ==		==Illustration of Skeletal Muscle==
	~~<gallery>~~		[[File:Blausen_0801_SkeletalMuscle.png\|Illustration of skeletal muscle\|thumb\|right]]
	File:~~Apararenone~~.~~svg~~\|~~Chemical structure~~ of ~~Apararenone~~
	~~</gallery>~~

	[[~~Category:Antihypertensive agents~~]]		==Related Pages==
	[[~~Category:Heart failure treatments~~]]		* [[Formoterol]]
	~~== Arformoterol ==~~		* [[Beta-2 adrenergic receptor]]
	~~<gallery>~~		* [[Chronic obstructive pulmonary disease]]
	~~File:Arformoterol.svg\|Chemical structure of Arformoterol~~		* [[Bronchodilator]]
	~~File~~:~~Arformoterol_ball~~-~~and-stick_model.png\|Ball-and-stick model of Arformoterol~~
	~~File~~:~~Blausen_0801_SkeletalMuscle.png\|Illustration of skeletal muscle~~		[[Category:Beta-2 adrenergic agonists]]
	~~</gallery>~~		[[Category:Drugs used in respiratory diseases]]

Prab: CSV import

2025-02-18T00:47:28Z

CSV import

← Older revision		Revision as of 00:47, 18 February 2025
Line 42:		Line 42:
	[[Category:Antihypertensive agents]]		[[Category:Antihypertensive agents]]
	[[Category:Heart failure treatments]]		[[Category:Heart failure treatments]]
			== Arformoterol ==
			<gallery>
			File:Arformoterol.svg\|Chemical structure of Arformoterol
			File:Arformoterol_ball-and-stick_model.png\|Ball-and-stick model of Arformoterol
			File:Blausen_0801_SkeletalMuscle.png\|Illustration of skeletal muscle
			</gallery>

Prab: CSV import

2025-02-11T17:37:27Z

CSV import

← Older revision		Revision as of 17:37, 11 February 2025
Line 1:		Line 1:
	'''Arformoterol''' is a long-acting [[beta2-adrenergic receptor agonist]] (LABA) used in the management of [[chronic obstructive pulmonary disease]] (COPD). It is a [[stereoisomer]] of [[formoterol]], specifically the (R,R)-enantiomer, which is believed to be the active form of the drug. Arformoterol works by relaxing the muscles in the airways and widening the airways in the lungs, which helps to improve breathing in individuals with COPD. It is administered through nebulization, making it suitable for patients who may have difficulties with handheld inhalers.		== Apararenone ==

	~~==Mechanism of Action==~~		'''Apararenone''' is a pharmaceutical compound that acts as a [[mineralocorticoid receptor antagonist]]. It is primarily used in the treatment of conditions such as [[hypertension]] and [[heart failure]]. Apararenone works by blocking the action of [[aldosterone]], a hormone that increases the reabsorption of sodium and water in the kidneys, leading to increased blood pressure.
	~~Arformoterol~~ acts ~~on the beta2-adrenergic receptors located~~ in the ~~smooth muscle of the airways. Activation~~ of ~~these receptors leads to an increase in intracellular cyclic adenosine monophosphate (cAMP) levels, resulting in bronchial smooth muscle relaxation~~ and ~~bronchodilation~~. ~~This~~ action ~~reduces airway resistance and facilitates airflow~~, ~~thereby alleviating symptoms~~ of ~~bronchospasm, wheezing,~~ and ~~shortness of breath~~ in ~~COPD patients~~.

	==~~Indications~~==		=== Mechanism of Action ===
	~~Arformoterol is indicated for~~ the ~~long-term~~, ~~twice-daily (morning~~ and ~~evening) maintenance treatment~~ of ~~bronchoconstriction in patients with COPD, including chronic bronchitis~~ and ~~emphysema~~. ~~It is not intended for~~ the ~~relief of acute symptoms of COPD or for~~ the ~~treatment of asthma, as its safety and efficacy have not been established in these conditions~~.		Apararenone functions by competitively inhibiting the binding of aldosterone to the mineralocorticoid receptor. This inhibition prevents the activation of the receptor, thereby reducing sodium reabsorption and promoting the excretion of sodium and water. This action helps to lower blood pressure and reduce the workload on the heart.

	==~~Contraindications and Precautions~~==		=== Clinical Uses ===
	~~Arformoterol~~ is ~~contraindicated~~ in ~~patients with a history~~ of ~~hypersensitivity~~ to ~~arformoterol, formoterol, or any of its components~~. It ~~should be used with caution~~ in ~~patients with cardiovascular disorders, especially coronary insufficiency, cardiac arrhythmias, and hypertension, due to~~ the ~~potential for increased~~ heart ~~rate, blood pressure,~~ and ~~cardiovascular effects associated with beta2-adrenergic agonists~~.		Apararenone is used in the management of:
			* [[Hypertension]]: By reducing blood volume and vascular resistance, apararenone helps to lower blood pressure.
			* [[Heart failure]]: It helps in reducing the symptoms of heart failure by decreasing fluid overload and improving cardiac function.

	==~~Side Effects~~==		=== Pharmacokinetics ===
	~~Common side effects of arformoterol include headache, tremor, dry mouth,~~ and ~~insomnia~~. ~~Less frequently, it can cause palpitations, chest pain,~~ and ~~hypokalemia~~. ~~As with other LABAs, there is a risk~~ of ~~asthma~~-~~related death when used in patients with asthma without a concomitant inhaled corticosteroid~~.		Apararenone is administered orally and is absorbed in the gastrointestinal tract. It undergoes hepatic metabolism and is excreted primarily through the kidneys. The pharmacokinetic profile of apararenone allows for once-daily dosing, which can improve patient compliance.

	==~~Drug Interactions~~==		=== Side Effects ===
	~~Arformoterol may interact with other medications, including beta~~-~~blockers~~, ~~which~~ can ~~reduce its effectiveness~~, and ~~diuretics, which can exacerbate hypokalemia. Caution should be exercised when prescribing arformoterol with other medications that prolong~~ the ~~QT interval or within 2 weeks of discontinuing monoamine oxidase inhibitors or tricyclic antidepressants~~.		Common side effects of apararenone include:
			* [[Hyperkalemia]]: Due to its potassium-sparing effects, there is a risk of elevated potassium levels in the blood.
			* [[Hypotension]]: Excessive lowering of blood pressure can occur, especially in patients with pre-existing low blood pressure.
			* [[Dizziness]] and [[fatigue]]: These are common due to the blood pressure-lowering effects.

	==~~Pharmacokinetics~~==		=== Contraindications ===
	Arformoterol is rapidly absorbed following inhalation and has a plasma half-life of approximately 26 hours, supporting its twice-daily dosing regimen. It is primarily metabolized by conjugation and excreted in the ~~urine and feces.~~		Apararenone should not be used in patients with:
			* Severe [[renal impairment]]
			* [[Hyperkalemia]]
			* Known hypersensitivity to the drug

	==~~Conclusion~~==		=== Drug Interactions ===
	~~Arformoterol~~ is ~~an effective long-acting beta2-adrenergic agonist for the maintenance treatment of COPD. Its long half-life allows for convenient twice-daily dosing. However, it should be~~ used with ~~caution in certain patient populations and is not suitable for the treatment of acute bronchospasm or asthma~~.		Apararenone can interact with other medications that affect potassium levels, such as [[ACE inhibitors]] and [[potassium supplements]]. Caution is advised when used concurrently with these agents.

	[[~~Category:Respiratory system drugs~~]]		== Related Pages ==
	[[~~Category:Beta2-adrenergic agonists~~]]		* [[Mineralocorticoid receptor antagonist]]
			* [[Aldosterone]]
			* [[Hypertension]]
			* [[Heart failure]]

	~~{{Pharmacology-stub}}~~		== Gallery ==
			<gallery>
			File:Apararenone.svg\|Chemical structure of Apararenone
			</gallery>

			[[Category:Antihypertensive agents]]
			[[Category:Heart failure treatments]]

Prab: CSV import

2024-03-22T10:45:59Z

CSV import

New page

'''Arformoterol''' is a long-acting [[beta2-adrenergic receptor agonist]] (LABA) used in the management of [[chronic obstructive pulmonary disease]] (COPD). It is a [[stereoisomer]] of [[formoterol]], specifically the (R,R)-enantiomer, which is believed to be the active form of the drug. Arformoterol works by relaxing the muscles in the airways and widening the airways in the lungs, which helps to improve breathing in individuals with COPD. It is administered through nebulization, making it suitable for patients who may have difficulties with handheld inhalers.

==Mechanism of Action==
Arformoterol acts on the beta2-adrenergic receptors located in the smooth muscle of the airways. Activation of these receptors leads to an increase in intracellular cyclic adenosine monophosphate (cAMP) levels, resulting in bronchial smooth muscle relaxation and bronchodilation. This action reduces airway resistance and facilitates airflow, thereby alleviating symptoms of bronchospasm, wheezing, and shortness of breath in COPD patients.

==Indications==
Arformoterol is indicated for the long-term, twice-daily (morning and evening) maintenance treatment of bronchoconstriction in patients with COPD, including chronic bronchitis and emphysema. It is not intended for the relief of acute symptoms of COPD or for the treatment of asthma, as its safety and efficacy have not been established in these conditions.

==Contraindications and Precautions==
Arformoterol is contraindicated in patients with a history of hypersensitivity to arformoterol, formoterol, or any of its components. It should be used with caution in patients with cardiovascular disorders, especially coronary insufficiency, cardiac arrhythmias, and hypertension, due to the potential for increased heart rate, blood pressure, and cardiovascular effects associated with beta2-adrenergic agonists.

==Side Effects==
Common side effects of arformoterol include headache, tremor, dry mouth, and insomnia. Less frequently, it can cause palpitations, chest pain, and hypokalemia. As with other LABAs, there is a risk of asthma-related death when used in patients with asthma without a concomitant inhaled corticosteroid.

==Drug Interactions==
Arformoterol may interact with other medications, including beta-blockers, which can reduce its effectiveness, and diuretics, which can exacerbate hypokalemia. Caution should be exercised when prescribing arformoterol with other medications that prolong the QT interval or within 2 weeks of discontinuing monoamine oxidase inhibitors or tricyclic antidepressants.

==Pharmacokinetics==
Arformoterol is rapidly absorbed following inhalation and has a plasma half-life of approximately 26 hours, supporting its twice-daily dosing regimen. It is primarily metabolized by conjugation and excreted in the urine and feces.

==Conclusion==
Arformoterol is an effective long-acting beta2-adrenergic agonist for the maintenance treatment of COPD. Its long half-life allows for convenient twice-daily dosing. However, it should be used with caution in certain patient populations and is not suitable for the treatment of acute bronchospasm or asthma.

[[Category:Respiratory system drugs]]
[[Category:Beta2-adrenergic agonists]]

{{Pharmacology-stub}}